Logo do repositório
 
Publicação

Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes

2024-05Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorSimões-Pereira, Joana
dc.contributor.authorSaramago, Ana
dc.contributor.authorRodrigues, Ricardo
dc.contributor.authorPojo, Marta
dc.contributor.authorPires, Carolina
dc.contributor.authorHorta, Mariana
dc.contributor.authorLópez-Presa, Dolores
dc.contributor.authorRito, Miguel
dc.contributor.authorCabrera, Rafael
dc.contributor.authorFerreira, Teresa C.
dc.contributor.authorLeite, Valeriano
dc.contributor.authorCavaco, Branca M.
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblHumana Press
dc.date.accessioned2023-12-28T22:32:55Z
dc.date.available2023-12-28T22:32:55Z
dc.date.issued2024-05
dc.descriptionFunding Information: This study was funded by iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344; UID/Multi/00462; UIDB/04462/2020), a program co-funded by Fundação para a Ciência e Tecnologia/Ministério da Ciência e do Ensino Superior, Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM), and Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). J.S.-P. was supported by iNOVA4Health – UIDB/04462/2020. M.P. was granted by Liga Portuguesa Contra o Cancro, Núcleo Regional do Sul (LPCC-NRS). R.R. was granted with a PhD scholarship by iNOVA4Health Research Unit - UIDP/04462/2020; UI/BD/154256/2022. C.P. was granted with a PhD scholarship by FCT – 2020.07120.BD. Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
dc.description.abstractPurpose: Radioiodine (RAI) therapy remains the gold-standard approach for distant metastatic differentiated thyroid cancer (TC). The main objective of our work was to identify the clinical and molecular markers that may help to predict RAI avidity and RAI therapy response of metastatic lesions in a cohort of papillary thyroid cancer (PTC) patients. Methods: We performed a retrospective analysis of 122 PTC patients submitted to RAI therapy due to distant metastatic disease. We also analysed, through next-generation sequencing, a custom panel of 78 genes and rearrangements, in a smaller cohort of 31 metastatic PTC, with complete follow-up, available RAI therapy data, and existing tumour sample at our centre. Results: The most frequent outcome after RAI therapy was progression of disease in 59.0% of cases (n = 71), with median estimate progression-free survival of 30 months. RAI avidity was associated with PTC subtype, age and stimulated thyroglobulin at first RAI therapy for metastatic disease. The most frequently altered genes in the cohort of 31 PTC patients’ primary tumours were RAS isoforms (54.8%) and TERT promoter (TERTp) (51.6%). The presence of BRAF p.V600E or RET/PTC alterations was associated with lower avidity (p = 0.012). TERTp mutations were not associated with avidity (p = 1.000) but portended a tendency for a higher rate of progression (p = 0.063); similar results were obtained when RAS and TERTp mutations coexisted (p = 1.000 and p = 0.073, respectively). Conclusions: Early identification of molecular markers in primary tumours may help to predict RAI therapy avidity, the response of metastatic lesions and to select the patients that may benefit the most from other systemic therapies.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent1210969
dc.identifier.doi10.1007/s12020-023-03633-y
dc.identifier.issn1355-008X
dc.identifier.otherPURE: 79232375
dc.identifier.otherPURE UUID: cc6c8787-044f-4264-a840-7d0a3de90b38
dc.identifier.otherScopus: 85179656959
dc.identifier.otherWOS: 001126015100001
dc.identifier.otherPubMed: 38102497
dc.identifier.urihttp://hdl.handle.net/10362/161725
dc.identifier.urlhttps://www.scopus.com/pages/publications/85179656959
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAvidity
dc.subjectMetastasis
dc.subjectPapillary thyroid cancer
dc.subjectRadioiodine therapy
dc.subjectRAS genes
dc.subjectTERT promoter
dc.subjectEndocrinology, Diabetes and Metabolism
dc.subjectEndocrinology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleClinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomesen
dc.typejournal article
degois.publication.firstPage625
degois.publication.issue2
degois.publication.lastPage634
degois.publication.titleEndocrine
degois.publication.volume84
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
s12020_023_03633_y.pdf
Tamanho:
1.15 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica